Anaphylaxis during pregnancy - 29/08/12
, Michael Schatz, MD, MSc bAbstract |
Anaphylaxis during pregnancy, labor, and delivery can be catastrophic for the mother and, especially, the infant. Symptoms and signs can include intense vulvar and vaginal itching, low back pain, uterine cramps, fetal distress, and preterm labor. During the first 3 trimesters, etiologies are similar to those in nonpregnant women. During labor and delivery, common etiologies are β-lactam antibiotics, natural rubber latex, and other agents used in medical and perioperative settings. Important caveats in management include injecting epinephrine (adrenaline) promptly, providing high-flow supplemental oxygen, positioning the mother on her left side to improve venous return to the heart, maintaining a minimum maternal systolic blood pressure of 90 mm Hg to ensure adequate placental perfusion, and continuous electronic monitoring. Cardiopulmonary resuscitation and emergency cesarean delivery should be performed when indicated. In all women of child-bearing age, allergy/immunology specialists can help to prevent anaphylaxis in pregnancy through prepregnancy risk assessment and risk reduction strategies, such as confirming the etiology of systemic allergic reactions, providing written instructions for allergen avoidance, and initiating relevant immune modulation. In pregnant women the benefits versus risks of skin tests, challenge tests, desensitization, and initiation of immunotherapy with allergens should be carefully weighed; if possible, these procedures should be deferred until after parturition. Prospective interdisciplinary studies of anaphylaxis during pregnancy are needed.
Le texte complet de cet article est disponible en PDF.Key words : Anaphylaxis, pregnancy, labor, delivery, penicillin allergy, neuromuscular blocker allergy, latex allergy, neonatal group B streptococcal infection, amniotic fluid embolism, resuscitation
Abbreviations used : AFE, GBS, NRL
Plan
| Disclosure of potential conflict of interest: F. E. R. Simons is a member of the ALK-Abelló Medical Advisory Board, the Mylan Medical Advisory Board, and the Sanofi Medical Advisory Board. M. Schatz declares that he has no relevant conflicts of interest. |
Vol 130 - N° 3
P. 597-606 - septembre 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
